Gamma-glutamyltransferase (GGT) is a cell-surface enzyme found mainly in the liver that initiates the extracellular breakdown of glutathione, the body's principal intracellular antioxidant, salvaging its constituent amino acids for renewed glutathione synthesis. Serum GGT has long been used clinically as a marker of liver and bile-duct disease and of alcohol intake. Because GGT activity is tightly linked to glutathione turnover and, in the presence of iron, can itself promote the generation of reactive oxygen species, circulating GGT even within the reference range is increasingly regarded as an early, sensitive marker of oxidative stress. A GGT blood test measures the level of this enzyme in the blood.
Large prospective cohorts and meta-analyses consistently link higher serum GGT, even within the reference range, to increased all-cause and cardiovascular mortality, incident hypertension, type 2 diabetes, metabolic syndrome and fatty liver, and some cancers, associations frequently interpreted through GGT's connection to oxidative stress. In UK Biobank data, people with high-normal GGT had a roughly threefold higher rate of liver-related death, and greater visit-to-visit GGT variability itself predicts mortality, heart attack and stroke. However, the evidence is observational: adding GGT to established risk models improves prediction only marginally, and a Mendelian-randomization study found no causal effect of GGT on diabetes, indicating much of the association may reflect confounding or reverse causation. GGT is nonspecific and is strongly influenced by alcohol, medications, adiposity and liver disease, so it cannot diagnose any single condition on its own and is best read alongside ALT, AST and ALP. This evidence describes the GGT biomarker and its physiology in human health and aging, not this specific commercial test product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“serum GGT may be useful for risk assessment of all-cause and disease-specific mortality”
“GGT activity turns out to be a critical biomarker for predicting long-term survival”
“GGT, even at physiologic high levels, predicted mortality, especially cardiovascular mortality and cancer mortality.”
“The pooled RR of CV mortality for highest vs. lowest GGT quartile was 1.52 (95% CI 1.36-1.70). The pooled RR of CV mortality for per unit-log (GGT) increment was 1.76 (95% CI 1.60-1.94).”
“These findings indicate that serum GGT activity within the reference interval is positively associated with increased risk of CV mortality in a dose-response manner.”
“Higher GGT levels are a risk factor for all-cause and cardiovascular disease death in people with and without diabetes. However, knowledge of GGT does not improve cardiovascular predictions beyond traditional risk factors.”
Research describes the active mechanism and is not a claim about this specific product.
Across large prospective cohorts and meta-analyses, lower grip strength is consistently…
Across large studies, dysregulated cortisol patterns track with worse health: a…
Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature…
Across large prospective cohorts and meta-analyses, higher hs-CRP is consistently…
Yes — its active compound is linked to 22 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.